Bcg Vaccine
drugOn this page
Also known as Bacillus calmette-guerin antigenliveBCG_THERAPIE
Summary
Bcg Vaccine (CHEMBL2108905) is a phase-3 clinical-stage vaccine component (ATC L03AX03); indicated across 19 conditions including respiratory system disorder and lung neoplasm.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Vaccine component
- ATC class: L03AX03
- Indications: 19 conditions
- Clinical trials: 37
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108905 |
| Name | Bcg Vaccine |
| Type | Vaccine component |
| Max phase | 3 |
| ATC | L03AX03 |
Also known as: Bacillus calmette-guerin antigen, Bcg vaccine, live, BCG_THERAPIE, BCG VACCINE
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
19 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| respiratory system disorder | 3 | MONDO:0005087 | EFO:0000684 |
| lung neoplasm | 3 | MONDO:0021117 | MONDO:0008903 |
| severe acute respiratory syndrome | 3 | MONDO:0005091 | MONDO:0100096 |
| neoplasm | 3 | MONDO:0005070 | EFO:0000616 |
| tuberculosis | 3 | MONDO:0018076 | MONDO:0018076 |
| colorectal neoplasm | 3 | MONDO:0005335 | MONDO:0005575 |
| cutaneous melanoma | 2 | MONDO:0005012 | EFO:0000389 |
| ovarian cancer | 2 | MONDO:0008170 | MONDO:0008170 |
| HIV infectious disease | 2 | MONDO:0005109 | EFO:0000764 |
| neuroblastoma | 1 | MONDO:0005072 | EFO:0000621 |
| sarcoma | 1 | MONDO:0005089 | EFO:0000691 |
| breast neoplasm | 1 | MONDO:0021100 | MONDO:0007254 |
| Alzheimer disease | 0 | MONDO:0004975 | MONDO:0004975 |
6 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 37.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 11 |
| PHASE2 | 8 |
| PHASE4 | 6 |
| PHASE1 | 4 |
| PHASE1/PHASE2 | 3 |
| PHASE2/PHASE3 | 2 |
| Not specified | 2 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04899765 | PHASE4 | RECRUITING | Measles and BCG Vaccines for Mother and Child |
| NCT06148025 | PHASE4 | RECRUITING | Antibiotics and Vaccine Immune Responses Study |
| NCT07005726 | PHASE4 | ENROLLING_BY_INVITATION | BCG Revaccination With the Third Dose of Diphtheria-tetanus-pertussis Vaccine and Infant Mortality in Africa |
| NCT04348370 | PHASE4 | COMPLETED | BCG Vaccine for Health Care Workers as Defense Against COVID 19 |
| NCT04414267 | PHASE4 | COMPLETED | Bacillus Calmette-guérin Vaccination to Prevent COVID-19 |
| NCT04417335 | PHASE4 | UNKNOWN | Reducing COVID-19 Related Hospital Admission in Elderly by BCG Vaccination |
| NCT00002490 | PHASE3 | COMPLETED | Radiation Therapy, Chemotherapy, or Observation in Treating Patients With Bladder Cancer |
| NCT00002990 | PHASE3 | COMPLETED | Surgery and BCG in Treating Patients With Bladder Cancer |
| NCT00003279 | PHASE3 | COMPLETED | Vaccination Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer |
| NCT00006352 | PHASE3 | COMPLETED | Monoclonal Antibody Therapy Plus BCG in Treating Patients With Limited-Stage Small Cell Lung Cancer |
| NCT00352079 | PHASE3 | TERMINATED | BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer |
| NCT00427570 | PHASE3 | COMPLETED | Fluorouracil, Semustine, and Vincristine Compared With BCG in Treating Patients With Dukes’ B or Dukes’ C Colon Cancer That Has Been Removed By Surgery |
| NCT02085590 | PHASE2/PHASE3 | COMPLETED | Effects of BCG on Immune Response |
| NCT04327206 | PHASE3 | COMPLETED | BCG Vaccination to Protect Healthcare Workers Against COVID-19 |
| NCT04328441 | PHASE3 | COMPLETED | Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine |
| NCT04461379 | PHASE3 | UNKNOWN | Prevention, Efficacy and Safety of BCG Vaccine in COVID-19 Among Healthcare Workers |
| NCT04534803 | PHASE3 | WITHDRAWN | BCG Against Covid-19 for Prevention and Amelioration of Severity Trial (BAC to the PAST) |
| NCT04938323 | PHASE2/PHASE3 | WITHDRAWN | Prevention of Acute Respiratory Infection in Taiwanese Institutionalized Elderly |
| NCT05330884 | PHASE3 | SUSPENDED | BCG Revaccination in Children and Adolescents |
| NCT00003386 | PHASE2 | TERMINATED | Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer |
| NCT00003715 | PHASE2 | TERMINATED | Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma |
| NCT00003759 | PHASE2 | COMPLETED | AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer |
| NCT00004122 | PHASE2 | COMPLETED | BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer |
| NCT00007826 | PHASE1/PHASE2 | UNKNOWN | Monoclonal Antibody Therapy and/or Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer |
| NCT00016133 | PHASE1/PHASE2 | COMPLETED | Vaccine Therapy in Treating Patients With Stage II or Stage III Colon Cancer That Has Been Removed During Surgery |
| NCT00023842 | PHASE2 | COMPLETED | BCG With or Without Mitomycin in Treating Patients With Bladder Cancer |
| NCT00514072 | PHASE2 | UNKNOWN | Vaccine Therapy in Treating Patients With Stage D0 Prostate Cancer |
| NCT01697306 | PHASE2 | COMPLETED | The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer |
| NCT04659941 | PHASE2 | UNKNOWN | Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers |
| NCT05539989 | PHASE1/PHASE2 | WITHDRAWN | Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa |
| NCT00003023 | PHASE1 | COMPLETED | Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer |
| NCT00003184 | PHASE1 | COMPLETED | Vaccine Therapy in Treating Women With Metastatic Breast Cancer |
| NCT01878188 | PHASE1 | COMPLETED | Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma |
| NCT04563273 | PHASE1 | COMPLETED | Clinical Study of BCG Vaccine for Intradermal Injection |
| NCT06078891 | EARLY_PHASE1 | ENROLLING_BY_INVITATION | Does BCG Vaccination Reduce Biomarkers of Alzheimer’s Disease? |
| NCT02444611 | Not specified | COMPLETED | A Trial Investigating the Influence of BCG and Hepatitis B Immunisation at Birth on Neonatal Immune Responses: The Early Life Vaccines and Immunity Study |
| NCT03548233 | Not specified | UNKNOWN | BCG Vaccination Scar Formation in Children Under Five Years :Factors Affecting Its Formation and Subsequent Adverse Effects . |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).